245 related articles for article (PubMed ID: 24188161)
1. Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study.
Trugman JM; Palmer RH; Ma Y
Curr Med Res Opin; 2014 Apr; 30(4):589-97. PubMed ID: 24188161
[TBL] [Abstract][Full Text] [Related]
2. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
Shimada K; Ogihara T; Saruta T; Kuramoto K;
Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
[TBL] [Abstract][Full Text] [Related]
3. Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia.
Saxe PA; Arnold LM; Palmer RH; Gendreau RM; Chen W
Curr Med Res Opin; 2012 May; 28(5):815-21. PubMed ID: 22429066
[TBL] [Abstract][Full Text] [Related]
4. Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program.
Arnold LM; Bateman L; Palmer RH; Lin Y
Pediatr Rheumatol Online J; 2015 Jun; 13():27. PubMed ID: 26112278
[TBL] [Abstract][Full Text] [Related]
5. Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial.
Clauw DJ; Mease PJ; Palmer RH; Trugman JM; Wang Y
Arthritis Res Ther; 2013 Aug; 15(4):R88. PubMed ID: 23953493
[TBL] [Abstract][Full Text] [Related]
6. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia.
Vitton O; Gendreau M; Gendreau J; Kranzler J; Rao SG
Hum Psychopharmacol; 2004 Oct; 19 Suppl 1():S27-35. PubMed ID: 15378666
[TBL] [Abstract][Full Text] [Related]
7. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
Luque Otero M; Martell Claros N;
Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479
[TBL] [Abstract][Full Text] [Related]
8. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.
Clauw DJ; Mease P; Palmer RH; Gendreau RM; Wang Y
Clin Ther; 2008 Nov; 30(11):1988-2004. PubMed ID: 19108787
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.
Arnold LM; Gendreau RM; Palmer RH; Gendreau JF; Wang Y
Arthritis Rheum; 2010 Sep; 62(9):2745-56. PubMed ID: 20496365
[TBL] [Abstract][Full Text] [Related]
10. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia.
Branco JC; Zachrisson O; Perrot S; Mainguy Y;
J Rheumatol; 2010 Apr; 37(4):851-9. PubMed ID: 20156949
[TBL] [Abstract][Full Text] [Related]
11. Effect of low-dose manidipine on ambulatory blood pressure in very elderly hypertensives.
Fogari R; Zoppi A; Mugellini A; Preti P; Corradi L; Lusardi P
Cardiovasc Drugs Ther; 1999 May; 13(3):243-8. PubMed ID: 10439887
[TBL] [Abstract][Full Text] [Related]
12. A pooled analysis of two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia.
Geisser ME; Palmer RH; Gendreau RM; Wang Y; Clauw DJ
Pain Pract; 2011; 11(2):120-31. PubMed ID: 20642487
[TBL] [Abstract][Full Text] [Related]
13. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study.
Goldenberg DL; Clauw DJ; Palmer RH; Mease P; Chen W; Gendreau RM
Pain Med; 2010 Feb; 11(2):180-94. PubMed ID: 20002596
[TBL] [Abstract][Full Text] [Related]
14. A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
Palma-Gamiz JL; Pêgo M; Marquez E; Pujol M; Olivan J; Alegría E; Sagastagoitia-Gorostiza JD; Gonzalez-Juanatey JR
Clin Drug Investig; 2007; 27(6):407-17. PubMed ID: 17506591
[TBL] [Abstract][Full Text] [Related]
15. A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia.
Arnold LM; Palmer RH; Ma Y
Clin J Pain; 2013 Dec; 29(12):1021-8. PubMed ID: 23446068
[TBL] [Abstract][Full Text] [Related]
16. Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study.
Branco JC; Cherin P; Montagne A; Bouroubi A;
J Rheumatol; 2011 Jul; 38(7):1403-12. PubMed ID: 21459941
[TBL] [Abstract][Full Text] [Related]
17. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
[TBL] [Abstract][Full Text] [Related]
18. Milnacipran: in fibromyalgia.
Chwieduk CM; McCormack PL
Drugs; 2010; 70(1):99-108. PubMed ID: 20030428
[TBL] [Abstract][Full Text] [Related]
19. [A Brazilian multicenter study to evaluate the clinical effectiveness and tolerance of isradipine SRO using ambulatory monitoring of arterial pressure in the treatment of mild and moderate arterial hypertension].
Magliano MF; Amodeo C; Mion Júnior D; Francischetti E; Lima Júnior E; Nobre F; Chaves H; Ribeiro JM; Spritzer N; Jardim PC
Arq Bras Cardiol; 1993 Nov; 61(5):311-8. PubMed ID: 8147731
[TBL] [Abstract][Full Text] [Related]
20. Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol.
Radauceanu A; Boivin JM; Bernaud C; Fay R; Zannad F;
Fundam Clin Pharmacol; 2004 Aug; 18(4):483-91. PubMed ID: 15312156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
